Sharp Metropolitan Medical Campus — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$568,206	32
2024	Research	$219,618	34
2023	Research	$89,483	19
2022	Research	$181	1
2021	Research	$99,702	14
2020	Research	$147,357	7
2019	Research	$49,775	14

Breakdown

Who paid Research payments · program years 2019–2025

AstraZeneca Pharmaceuticals LP $879,474 36 payments
Novo Nordisk AS $162,293 72 payments
AstraZeneca UK Limited $109,305 11 payments
Celgene Corporation $23,250 2 payments

Studies the money was for Research payments · program years 2019–2025

A Phase III, double-blind, placebo-controlled, Randomized, Multicenter, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced Stage III, Unresectable Non-small Cell Lung Cancer NSCLC $341,155 3 payments
A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer $181,972 9 payments
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) $159,126 4 payments
Nn6535-4725 $157,694 70 payments
A Phase III Randomized Double blind Multicenter Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum based Chemotherapy for the First line Treatment of Patients with Metastatic Non squamous Non small Cell Lung Cancer Whose Tumors Express PDL1 ARTEMIDE Lung03 $74,070 1 payment
CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 $52,062 2 payments
A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) $30,650 1 payment
A Phase III, Open-label, Randomized Study of Osimertinib with or without Datopotamab deruxtecan (Dato-DXd), as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer $26,000 1 payment
A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non Small Cell Lung Cancer $24,284 6 payments
A Randomised,Double blind,Placebo controlled,Adaptive,Population Enrichment Phase III Study of AZD5305 in Men with Metastatic Castration sensitive Prostate Cancer Receiving Physician is Choice New Hormonal Agents $23,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.